News / Taiwan / cnyes
BoneCare Biotech Targets Orthopedic Regeneration and Infectious Disease Markets
Health Technology · Biotechnology · cnyes · 2026-08-31
6733
BoneCare Biotech outlines its dual-core strategy in orthopedic regeneration and infectious disease, highlighting global licensing progress and clinical trial milestones.
What Happened
Strategic Focus: BoneCare Biotech has solidified its business strategy around orthopedic regeneration and infectious disease treatments, aiming to deepen its domestic presence while accelerating international licensing. The company reported a 14.22% year-on-year revenue growth for the first half of 2026, with reduced losses reflecting improved operational efficiency.
Product Milestones: The flagship product, RecoCart, has surpassed 1,200 clinical applications and secured a new U.S. patent valid until 2044. The company is pursuing a dual-track approach for U.S. market licensing while advancing regulatory and insurance approvals across Europe and Asia.
Clinical Pipeline: The company plans to initiate Phase III clinical trials for its Osteoinductive Factor (OIF) in Japan by Q1 2027, with a Taiwan application expected in Q4 this year. Additionally, BoneCare is preparing multiple physician-initiated studies to expand clinical applications in bone repair.
Infectious Disease Expansion: The production capacity for Menocik has been scaled up sixfold, contributing to steady revenue growth. BoneCare expects to launch new infectious disease products in 2027 and 2028 to further diversify its medical portfolio.